跳至主要内容
临床试验/NCT02993302
NCT02993302已完成2 期

Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients

Dr Cipto Mangunkusumo General Hospital0 个研究点目标入组 25 人开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
25
主要终点
CD80 Level

研究概览

简要总结

Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves' disease (GD), DCs have more active immune responses than those in healthy subjects. Our previous study demonstrated immunoregulatory effects of in vitro 1,25-D3 on maturation of DC in GD patients. This study aims to evaluate the effect of oral 1α-D3 on DC maturation in GD patients.

详细描述

Patients with Graves' disease were divided into two groups: groups receiving oral 1α-D3 in addition to propylthiouracil (PTU) and groups receiving placebos in addition to PTU. Comparison of DC maturation were performed before and after the oral 1α-D3. DC maturation was assessed based on the expression of DC markers (HLA-DR, CD80, CD40, CD83, CD14 and CD206) and the ratio of cytokines interleukin-12/IL-10.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with Graves' disease and still have not gone into remission
  • Willing to participate in the research

排除标准

  • Pregnant patient
  • Suffered from severe liver disease
  • Suffered from severe kidney disease
  • Taking vitamin D substitution therapy
  • Suffered from another autoimmune disease
  • Suffered from malignancy

研究组 & 干预措施

PTU-Oral 1α-D3

Active Comparator

patients were given oral 1α-D3 at dose of 1.5 mcg once daily for 8 weeks in addition to propylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis

干预措施: 1α-D3 (Drug)

PTU-Placebos

Placebo Comparator

patients were given placebo tablets for 8 weeks in addition topropylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis

干预措施: Placebos (Drug)

结局指标

主要结局

CD80 Level

时间窗: 1 year

Dendritic cells maturation levels were measured by the CD80 (cluster of differentiation 80)

CD206 Level

时间窗: 1 year

Dendritic cells maturation levels were measured by the CD206

IL-12/IL-10 Ratio

时间窗: 1 year

Dendritic cells maturation levels were measured by the IL-12 (interleukin-12)/IL-10 ratio

fT4 Levels

时间窗: 1 year

fT4 (free thyroxine)

次要结局

未报告次要终点

研究者

发起方
Dr Cipto Mangunkusumo General Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dyah Purnamasari

M.D., Ph.D

Dr Cipto Mangunkusumo General Hospital

相似试验

Effects Of Oral Alfacalcidol On Maturation Of... | 临床试验